Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2025)

Arcus Biosciences has reported Non-Current Assets over the past 9 years, most recently at $132.0 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $132.0 million for Q4 2025, down 1.49% from a year ago — trailing twelve months through Dec 2025 was $503.0 million (down 30.24% YoY), and the annual figure for FY2025 was $132.0 million, down 1.49%.
  • Non-Current Assets for Q4 2025 was $132.0 million at Arcus Biosciences, up from $117.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for RCUS hit a ceiling of $330.0 million in Q4 2021 and a floor of $93.2 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $233.5 million (2022), compared with a mean of $209.7 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 2018.78% in 2021 and later tumbled 49.24% in 2024.
  • Arcus Biosciences' Non-Current Assets stood at $330.0 million in 2021, then decreased by 29.39% to $233.0 million in 2022, then increased by 13.3% to $264.0 million in 2023, then tumbled by 49.24% to $134.0 million in 2024, then fell by 1.49% to $132.0 million in 2025.
  • The last three reported values for Non-Current Assets were $132.0 million (Q4 2025), $117.0 million (Q3 2025), and $129.0 million (Q2 2025) per Business Quant data.